Jared Henderson

Jared Henderson

Auto-generated profile, based on publicly available information

Jared Henderson

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
GHGuangchun Han
Guangchun Han
QDQing Deng
Qing Deng
MMMario L. Marques-Piubelli
Mario L. Marques-Piubelli
EDEnyu Dai
Enyu Dai
MDMinghao Dang
Minghao Dang
Michael GreenMichael Green
Michael Green
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified major phenotypic subsets of FL T cells, including a cytotoxic CD4 T-cell population. We characterized four major FL subtypes with differential representation or relative depletion of distinct T-cell subsets. By integrating exome sequencing, we observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells. In turn, expression of MHCII genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T cells. This provides a classification framework of the FL microenvironment in association with FL genotypes and MHC expression, and informs different potential immunotherapeutic strategies based upon tumor cell MHCII expression. Significance: We have characterized the FL-infiltrating T cells, identified cytotoxic CD4 T cells as an important component that is associated with tumor cell–intrinsic characteristics, and identified sets of targetable immune checkpoints on T cells that differed from FLs with normal versus low MHC expression. See related commentary by Melnick, p. 374. This article is highlighted in the In This Issue feature, p. 369

24 August 2017 in Blood
Verified
Journal Article
Closed access
PDF file
OHOndrej Havranek
Ondrej Havranek
JXJingda Xu
Jingda Xu
SKStefan Köhrer
Stefan Köhrer
ZWZhiqiang Wang
Zhiqiang Wang
LBLisa Becker
Lisa Becker
RDR. Eric Davis
R. Eric Davis
Key Points: The GCB subtype of DLBCL relies exclusively on tonic BCR signaling via CD79A Y188. PTEN protein expression and BCR surface density determine the contribution of tonic BCR signaling to AKT activity in GCB-DLBCL.

21 October 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YDYibo Dai
Yibo Dai
AKAtish Kizhakeyil
Atish Kizhakeyil
DCDai Chihara
Dai Chihara
XLXubin Li
Xubin Li
YLYunhe Liu
Yunhe Liu
Michael GreenMichael Green
Michael Green
Diffuse large B cell lymphomas (DLBCLs) are a heterogeneous group of malignancies that can arise in lymph nodes or extranodal locations, including immune-privileged sites. Here, we applied highly multiplexed spatial transcriptomics and proteomics together with genomic profiling to characterize the immune microenvironment architecture of 78 DLBCL tumors. We define seven distinct cellular niches, each characterized by unique cellular compositions, spatial organizations and patterns of intercellular communication associated with niche-specific phenotypes of both T cells and tumor B cells. Among these, DLBCLs from immune-privileged sites showed abundant T cell infiltration into diffuse niches, where immune cells were intermixed with tumor B cells and bore transcriptional hallmarks of activation and effector function, suggesting that they may be primed for anti-tumor immunity. Spatial characterization of the DLBCL immune microenvironment, therefore, reveals cellular niches that foster divergent patterns of cell–cell interactions contributing to the phenotypic heterogeneity of both niche-resident tumor and immune cells.

29 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
Paolo StratiPaolo Strati
Paolo Strati
LFLei Feng
Lei Feng
ATAndrey Tyshevich
Andrey Tyshevich
DSDarya Shavronskaya
Darya Shavronskaya
JAJulia Alesse
Julia Alesse
CFChristopher R. Flowers
Christopher R. Flowers
Purpose: SIRPα+ macrophages can mediate resistance to lenalidomide and rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel CD47 blocker that abrogates interactions between lymphoma cells and SIRPα+ macrophages. Patients and Methods: Adult patients with B-NHL who had received at least two prior lines of systemic therapy were included in this single-arm phase I study (NCT05025800). Evorpacept was administered intravenously, in a 28-day cycle, until progression at two dose levels (DL): 30 mg/Kg on day (D) 1 and D15 (DL1) or 60 mg/Kg on day 1 (DL2); rituximab 375 mg/m2 i.v. was given weekly during cycle 1 and on D1 during cycles 2 to 6; and lenalidomide 20 mg was given orally from D1 to D21 during cycles 1 to 6. Single-cell RNA sequencing was performed on tumor biopsies collected before treatment and during cycle 1. Results: Twenty patients were included in this study. The median age was 61 (27–85) years, and 18 patients (90%) had indolent B-NHL. Three patients were treated at DL1, 17 at DL2, and no dose-limiting toxicity was observed. The most common grade 3 to 4 adverse events included neutropenia (60%), infections (30%), and alanine transferase increase (15%). Sixteen (80%) patients achieved complete response, and after a median follow-up of 28 months, 2-year progression-free survival rate was 69%. During treatment, a significant increase in T cells and macrophages was observed, and macrophage pathways associated with anti-tumoral activity were upregulated. Conclusions: Evorpacept plus lenalidomide and rituximab has a safe toxicity profile and promising anti-tumoral activity, and induces favorable biological effects on the tumoral immune microenvironment.

15 July 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KVKamala Vanarsa
Kamala Vanarsa
JHJared Henderson
Jared Henderson
SSSanam Soomro
Sanam Soomro
LQLing Qin
Ling Qin
TZTing Zhang
Ting Zhang
CMChandra Mohan
Chandra Mohan
Our recent study has implicated bradykinin (BK) signaling as being of pathogenic importance in lupus. This study aims to investigate the biomarker potential of BK peptides, BK and BK-des-arg-9, in lupus and other rheumatic autoimmune diseases. Sera from systemic lupus erythematosus (SLE) patients and healthy subjects were screened for BK and BK-des-arg-9 by liquid chromatography–mass spectrometry metabolomics. Serum from 6-mo-old C57BL/6 mice and three murine lupus strains were also screened for the two peptides by metabolomics. Given the promising initial screening results, validation of these two peptides was next conducted using multiple reaction monitoring in larger patient cohorts. In initial metabolomics screening, BK-des-arg-9 was 22-fold higher in SLE serum and 106-fold higher in mouse lupus serum compared with healthy controls. In validation assays using multiple reaction monitoring and quadrupole time-of-flight mass spectrometry, BK and BK-des-arg-9 showed significant elevations in SLE serum compared with controls (p < 0.0001; area under the curve = 0.79–0.88), with a similar but less pronounced increase being noted in rheumatoid arthritis serum. Interestingly, increased renal SLE disease activity index in lupus patients was associated with reduced circulating BK-des-arg-9, and the reasons for this remain to be explored. To sum, increased conversion of BK to the proinflammatory metabolite BK-des-arg-9 appears to be a common theme in systemic rheumatic diseases. Besides serving as an early marker for systemic autoimmunity, independent studies also show that this metabolic axis may also be a pathogenic driver and therapeutic target in lupus. Key Points Serum BK-des-arg-9 is significantly elevated in mice and patients with lupus. A similar but less pronounced increase is also noted in RA serum. Increased conversion of BK to proinflammatory BK-des-arg-9 may mediate nephritis. Visual Abstract

20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.